Comparative Pharmacology
Head-to-head clinical analysis: DEPO MEDROL versus FLAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPO MEDROL versus FLAC.
DEPO-MEDROL vs FLAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylprednisolone acetate is a synthetic glucocorticoid receptor agonist that modulates gene expression to suppress inflammation, immune responses, and adrenal function by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
FLAC (Fluorouracil) is a pyrimidine analog that inhibits thymidylate synthase, blocking DNA synthesis. It is converted to active metabolites (FdUMP, FUTP) that disrupt RNA function and DNA replication.
IV: 10-40 mg every 1-2 weeks; IM: 40-120 mg every 1-4 weeks; Intra-articular/soft tissue: 4-80 mg per injection, repeat every 1-5 weeks as needed.
Adults: 40 mg orally twice daily.
None Documented
None Documented
Plasma terminal elimination half-life: 2.5-4.0 hours (methylprednisolone acetate formulation). Duration of adrenal suppression correlates with tissue esterase hydrolysis and prolonged tissue retention.
2-4 hours; prolonged in renal impairment (up to 12 hours)
Primarily hepatic metabolism; renal excretion of metabolites (<10% unchanged). Fecal excretion is minor (<5%).
Renal: 70% unchanged; Fecal: 20%; Biliary: 10%
Category C
Category C
Corticosteroid
Corticosteroid